Home › NASDAQ: MDWD
loading

KEY STATS

Previous Close:
$10.74
Market Cap:
$97.40M
24h Volume:
2,696
1D Range:
$10.28 - $10.56
52W Range:
$7.10 - $14.58
Primary Exchange:

COMPANY PROFILE

NameNameMediWound Ltd. - Ordinary Share
sectorSectorHealthcare (1499)
industryIndustryBiotechnology (867)
webWebmediwound.com
phonePhone972 7 797 14100
employeeEmployee76
chart-line-icon Latest SEC Filings
twitter-icon MDWD's Discussions on Twitter
location42 Hayarkon Street, Yavne, Israel (8122745)

UPGRADES & DOWNGRADES

Initiated Maxim Group: Buy Dec-22-22
Resumed Oppenheimer: Outperform Jul-18-22
Initiated BTIG Research: Buy Sep-23-20
Initiated Aegis Capital: Buy Nov-28-16
Initiated Wells Fargo: Outperform Aug-17-16
Initiated Oppenheimer: Outperform Apr-16-14
More Upgrades & Downgrades
News Price History Option Chain Financials Insider Trading Why MDWD Down? Discussions Forecast Stock Split Dividend History

MediWound Ltd. - Ordinary Share Stock (MDWD) Latest News

thumbnail
pulisher
Zacks Investment Research

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?
thumbnail
pulisher
Benzinga

HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know
thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
thumbnail
pulisher
Benzinga

What 4 Analyst Ratings Have To Say About MediWound
thumbnail
pulisher
Zacks Investment Research

MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates
thumbnail
pulisher
GlobeNewswire Inc.

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
thumbnail
pulisher
Zacks Investment Research

Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
thumbnail
pulisher
Zacks Investment Research

Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates
thumbnail
pulisher
Zacks Investment Research

Zoetis (ZTS) Beats Q2 Earnings and Revenue Estimates
thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces Commercial Launch of NexoBrid® in Japan
thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
thumbnail
pulisher
GlobeNewswire Inc.

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
thumbnail
pulisher
GlobeNewswire Inc.

MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
thumbnail
pulisher
Zacks Investment Research

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
thumbnail
pulisher
GlobeNewswire Inc.

MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023

About MediWound Ltd. - Ordinary Share

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Open in Yahoo | Open in Google | Open in Finviz
Cap:     |  Volume (24h):